Business Wire

Oral-B Encourages Consumers to Brush up on Their Oral Care Regimen and Recognise Its Importance to Overall Body Health

Share

Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact chronic periodontal diseases have on wider systemic disease.

The brand is leading the way in innovation, technology and research to help protect oral health and educate about the important connection between oral and overall body health. As part of the year-long partnership, Oral-B and Scientific American Custom Media are releasing a series of content, including educational resources from leading medical and dental researchers that will help readers better understand the connections between oral health and whole body health.

Oral diseases are at crisis level as it is estimated that they affect nearly 3.5 billion people worldwidei and in the midst of a global health pandemic, it is more crucial than ever to safeguard not only your oral health but your whole-body health too.

Jeremy A. Abbate, VP & Publisher at Scientific American explains: “Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health. It’s proven that periodontitis increasingly poses a significant risk to the development and progression of multiple systemic conditions and gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”

While warning signs can be as small as bleeding gums or even tooth loss, they can lead to more severe conditions such as heightened pregnancy complications, cognitive loss, poor diabetes control, and increases the risk of cardiovascular disease.

SYSTEMIC SPREAD OF PLAQUE BACTERIA THROUGHOUT THE BODY

A healthy mouth has minimal plaque build-up, ensuring oral bacteria cannot multiply, cause cavities, gum deterioration or spread beyond the mouth. However, when plaque build-up is present around the gum line and between teeth, it shelters oral bacteria (including P.gingivalis) from your toothbrush and natural defences. This provides the perfect conditions for the bacteria to thrive and cause inflammation-causing toxins that are known to spread throughout the rest of the body.

The formation of gum disease begins when plaque containing millions of bacteria coats the teeth, accumulates undisturbed. Acid produced by the bacteria can erode tooth enamel causing cavities and irritate the gums and cause gingivitis which can progress into periodontitis – a more serious infection that can lead to tooth loss.

When oral conditions worsen, the hidden plaque bacteria can cause an inflammatory response in the periodontal tissues that sets off a chain reaction, spreading systemically through the body via the circulatory system to other parts of the body. These oral bacteria are also found to be transmitted via the lungs and gastrointestinal tract.

DISEASES IMPACTED BY GUM DISEASE

  1. StrokePeriodontitis may increase the risk for stroke. A continuous flow of bacteria into the bloodstream from exacerbated gum sites can trigger inflammation, prompting plaque growth and leading to blood clots.ii
  2. Diabetes - There is a two-way relationship between diabetes and periodontitis, with more severe periodontal tissue destruction observed in diabetic populations, due to poorly controlled glucose levels.iiiiv
  3. Heart disease - Patients with periodontal disease are at increased risk for cardiovascular disease. Chronic gum inflammation may cause bad bacteria and toxins to enter the bloodstream and circulate to plaque sites in arterial walls.v
  4. Pregnancy gingivitis - Pregnant women are at increased risk of gingivitis and pregnant women with periodontitis are at increased risk for adverse pregnancy outcomes, including pre-term birth, low birth weight babies, and pregnancy hypertension (pre-eclampsia).vi
  5. Dementia - Patients with Alzheimer’s Disease and cognitive function loss have a higher risk for developing poor oral hygiene and periodontal disease. The relationship is bi-directional, as periodontal bacteria can also infect the brain and play a direct role in the build-up of amyloid brain lesions, leading to Alzheimer’s disease.vii

MAINTAINING A HEALTHY MOUTH AND BODY

Oral-B, the No.1 Dentist Recommended Toothbrush Brand Worldwide, is on a mission to make the invisible connection between oral health and whole-body wellness visible and to empower people to take their health into their own hands.

Following a daily holistic Oral-B regimen can help with maintaining a happy, healthy mouth:

  • Electric Toothbrush with a Round-Head
    Oral-B brushes are round for a reason, to adapt to each individual tooth and reach between the teeth. The Oral-B iO’s revolutionary technology removes 100% more plaque than a manual brush to give you that professional clean feeling every single day.
  • Stannous Fluoride Toothpaste
    Stannous Fluoride (SnF2) helps to protect your gums against bacterial plaque.
  • Mouth Rinse
    Mouth rinses containing bioavailable Cetylpyridinium Chloride (CPC) formulated at 0.07% helps to reduce plaque.
  • Interdental Cleaning
    Plaque easily accumulates and hides between teeth where toothbrushing can’t reach. Regular cleaning between teeth helps to remove plaque and helps protect gums.
  • Regular Oral-Health Check-Ups
    Partner with your dental professional regularly to prevent and detect signs of gum infection at its earliest stages.

Scientific American educational resources developed in partnership with Oral B can be found here.

####

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by Dr. Robert Hutson, a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Artificial Intelligencery®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.


i Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)

ii Janket SJ, Baird AE, Chuang SK, Jones JA. Meta- analysis of periodontal disease and risk for coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:559-569

iii Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998;3:51-61

iv Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: A two-way relationship. Diabetologia 2012;55:21-31.

v Blaizot A, Vergenes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: Meta-analyseis of observational studies. Int Dent J 2009; 59(4):197-209

vi Daalderop LD,Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF. Periodontal disease and pregnancy outcomes: Overview of systematic reviews. JDR Clinl Transl Res 2018;3:10-27. | Manrique-Corredor EJ, Orozco-Beltran D, Lopez-Pineda A, Quesada JA, Gil-Guillen VF, Carratala-Munuera C. Maternal periodontitis and preterm birth: systematic review and meta-analysis. Community Dent Oral Epidemiol 2019;47:243-251. | Chambrone L, Guglielmetti MR, Pannati CM, Chambrone LA. Evidence grade associating periodontitis to preterm birth and/or low birth weight: I. A systematic review of prospective cohort studies. J Clin Periodontol 2011;38:795-808. | Wei BJ, Chen YJ, Wu B. Periodontal disease and risk of preeclampsia: A meta- analysis of observational studies. PLOS ONE 2013;8:1-6. | Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol. 2008;Jan:7-22

vii Savitt ED, Socransky SS. Distribution of certain subgingival microbial species in selected periodontal conditions. J Periodontal Res 1984, 19 (2): 111-123.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Oral-B press team
Jemma Western
oralb@publicisgroupe.net

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release

Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release

The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th

Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release

Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor

Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release

Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye